Hookipa Pharma Inc (HOOK) Stock: A Look at the Monthly Trend

In the past week, HOOK stock has gone up by 5.30%, with a monthly decline of -6.42% and a quarterly plunge of -8.78%. The volatility ratio for the week is 5.14%, and the volatility levels for the last 30 days are 6.17% for Hookipa Pharma Inc The simple moving average for the past 20 days is 2.79% for HOOK’s stock, with a 11.52% simple moving average for the past 200 days.

Is It Worth Investing in Hookipa Pharma Inc (NASDAQ: HOOK) Right Now?

The 36-month beta value for HOOK is also noteworthy at 1.00. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for HOOK is 59.47M, and at present, short sellers hold a 0.56% of that float. The average trading volume of HOOK on April 03, 2024 was 548.75K shares.

HOOK) stock’s latest price update

Hookipa Pharma Inc (NASDAQ: HOOK) has seen a decline in its stock price by -0.38 in relation to its previous close of 0.76. However, the company has experienced a 5.30% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-22 that HOOKIPA Pharma Inc. (HOOK) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.17 per share a year ago.

Analysts’ Opinion of HOOK

Many brokerage firms have already submitted their reports for HOOK stocks, with BofA Securities repeating the rating for HOOK by listing it as a “Underperform.” The predicted price for HOOK in the upcoming period, according to BofA Securities is $0.50 based on the research report published on December 02, 2022 of the previous year 2022.

Morgan Stanley gave a rating of “Equal-Weight” to HOOK, setting the target price at $6 in the report published on November 12th of the previous year.

HOOK Trading at 7.73% from the 50-Day Moving Average

After a stumble in the market that brought HOOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -63.07% of loss for the given period.

Volatility was left at 6.17%, however, over the last 30 days, the volatility rate increased by 5.14%, as shares sank -5.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.92% upper at present.

During the last 5 trading sessions, HOOK rose by +4.45%, which changed the moving average for the period of 200-days by -29.81% in comparison to the 20-day moving average, which settled at $0.7343. In addition, Hookipa Pharma Inc saw -6.53% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at HOOK starting from Kandera Reinhard, who purchase 7,000 shares at the price of $0.72 back on Aug 21 ’23. After this action, Kandera Reinhard now owns 43,092 shares of Hookipa Pharma Inc, valued at $5,075 using the latest closing price.

Kandera Reinhard, the Chief Financial Officer of Hookipa Pharma Inc, purchase 8,000 shares at $0.71 during a trade that took place back on Aug 16 ’23, which means that Kandera Reinhard is holding 36,092 shares at $5,712 based on the most recent closing price.

Stock Fundamentals for HOOK

Current profitability levels for the company are sitting at:

  • -4.22 for the present operating margin
  • 0.82 for the gross margin

The net margin for Hookipa Pharma Inc stands at -4.06. The total capital return value is set at -0.71. Equity return is now at value -84.81, with -49.18 for asset returns.

Based on Hookipa Pharma Inc (HOOK), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -8.77. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -387.8.

Currently, EBITDA for the company is -81.38 million with net debt to EBITDA at 1.4. When we switch over and look at the enterprise to sales, we see a ratio of -1.71. The receivables turnover for the company is 1.04for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.

Conclusion

In summary, Hookipa Pharma Inc (HOOK) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts